Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aerpio Pharmaceuticals stock

Own Aerpio Pharmaceuticals stock in just a few minutes.

Aerpio Pharmaceuticals, Inc is a biotechnology business based in the US. Aerpio Pharmaceuticals shares (ARPO) are listed on the NASDAQ and all prices are listed in US Dollars. Aerpio Pharmaceuticals employs 12 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Aerpio Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARPO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Aerpio Pharmaceuticals share price

Use our graph to track the performance of ARPO stocks over time.

Aerpio Pharmaceuticals shares at a glance

Information last updated 2021-04-30.
52-week range$0.57 - $2.29
50-day moving average $1.36
200-day moving average $1.44
Wall St. target price$1.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.28

Buy Aerpio Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aerpio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aerpio Pharmaceuticals financials

Revenue TTM $15 million
Gross profit TTM $15 million
Return on assets TTM -9.36%
Return on equity TTM -10.84%
Profit margin -28.77%
Book value $0.91
Market capitalisation $55.8 million

TTM: trailing 12 months

Shorting Aerpio Pharmaceuticals shares

There are currently 1.3 million Aerpio Pharmaceuticals shares held short by investors – that's known as Aerpio Pharmaceuticals's "short interest". This figure is 26.6% up from 988,409 last month.

There are a few different ways that this level of interest in shorting Aerpio Pharmaceuticals shares can be evaluated.

Aerpio Pharmaceuticals's "short interest ratio" (SIR)

Aerpio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aerpio Pharmaceuticals shares currently shorted divided by the average quantity of Aerpio Pharmaceuticals shares traded daily (recently around 1.8 million). Aerpio Pharmaceuticals's SIR currently stands at 0.7. In other words for every 100,000 Aerpio Pharmaceuticals shares traded daily on the market, roughly 700 shares are currently held short.

However Aerpio Pharmaceuticals's short interest can also be evaluated against the total number of Aerpio Pharmaceuticals shares, or, against the total number of tradable Aerpio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aerpio Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Aerpio Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0355% of the tradable shares (for every 100,000 tradable Aerpio Pharmaceuticals shares, roughly 36 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aerpio Pharmaceuticals.

Find out more about how you can short Aerpio Pharmaceuticals stock.

Aerpio Pharmaceuticals share dividends

We're not expecting Aerpio Pharmaceuticals to pay a dividend over the next 12 months.

Aerpio Pharmaceuticals share price volatility

Over the last 12 months, Aerpio Pharmaceuticals's shares have ranged in value from as little as $0.565 up to $2.29. A popular way to gauge a stock's volatility is its "beta".

ARPO.US volatility(beta: 1.73)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aerpio Pharmaceuticals's is 1.725. This would suggest that Aerpio Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aerpio Pharmaceuticals overview

Aerpio Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site